Skip to main content
. 2018 Jan 26;13(1):e0191722. doi: 10.1371/journal.pone.0191722

Fig 2. Cumulative incidence and hazard ratios of stroke/systemic embolism among 5 mg BID apixaban/warfarin patients.

Fig 2

(A) Cumulative incidence of stroke/SE among propensity-score–matched 5 mg BID apixaban and warfarin patients. (B) Hazard ratios of stroke/SE for propensity-score–matched 5 mg BID apixaban and warfarin patients. BID, twice daily; stroke/SE, stroke/systemic embolism.